Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer's and Parkinson's, has entered definitive agreements for a registered direct offering expected to raise approximately $3.4 million. The offering consists of 1,670,732 shares of common stock priced at $2.05 per share, matching the closing price on October 24, 2025. The transaction is being led by H.C. Wainwright & Co. as the exclusive placement agent and includes participation from Chairman Michael Hoffman and CEO Dr. Maria Maccecchini. Closing is anticipated on or about October 28, 2025, with proceeds designated for working capital and general corporate purposes.
This capital infusion comes at a critical time for Annovis as it advances its lead drug candidate, buntanetap, which targets multiple pathways involved in neurodegeneration. The company is conducting late-stage clinical trials for both Alzheimer's and Parkinson's diseases, aiming to address the significant unmet medical needs in these areas. The additional funding will support ongoing research and development activities, including patient enrollment, data analysis, and regulatory preparations.
The participation of company insiders, including the CEO and Chairman, underscores confidence in Annovis's pipeline and strategic direction. According to the press release, the offering is structured as a registered direct offering, which allows for a more efficient capital-raising process compared to traditional public offerings. H.C. Wainwright's involvement as placement agent also lends credibility to the transaction, given its experience in the healthcare and biotechnology sectors.
For investors, this offering represents a potential opportunity to support a company with a dual focus on Alzheimer's and Parkinson's, two of the most prevalent neurodegenerative disorders. The $3.4 million in gross proceeds, while modest, may be sufficient to fund near-term milestones, such as interim trial results or interactions with regulatory agencies. However, the company may need additional capital in the future to complete pivotal trials and commercialize any approved therapies.
The full details of the offering are available in the company's newsroom at https://ibn.fm/ANVS. Investors and stakeholders can also access the complete press release at https://ibn.fm/d1q9Q for more information on the terms and conditions of the transaction.
